Information Provided By:
Fly News Breaks for January 31, 2020
VRTX
Jan 31, 2020 | 08:24 EDT
SunTrust analyst Robyn Karnauskas raised her price target on Vertex to $285 and kept her Buy rating, saying its CF revenues are being derisked by the recent approval and early launch metrics of its Trikafta drugs. The analyst believes that the company's pipeline will evolve further this year, giving investors confidence about its potential to diversify beyond CF.
News For VRTX From the Last 2 Days
There are no results for your query VRTX